ANDREW JACKENHEIMER: Open Payments
NPI 1346569928 · SEATTLE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,329 in 61 payments from 15 companies in 2025. Trend: 2023 $307 · 2024 $521 · 2025 $1,329
Food & beverage: $1,329
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $274 |
| Vanda Pharmaceuticals Inc. | 8 | $167 |
| Axsome Therapeutics, Inc. | 6 | $154 |
| ABBVIE INC. | 4 | $103 |
| Alkermes, Inc. | 4 | $101 |
| Janssen Pharmaceuticals, Inc | 4 | $99 |
| Otsuka America Pharmaceutical, Inc. | 4 | $86 |
| Collegium Pharmaceutical, Inc. | 4 | $78 |
| Teva Pharmaceuticals USA, Inc. | 2 | $56 |
| Neurocrine BioSciences, Inc. | 2 | $49 |
Products named: CAPLYTA, FANAPT, Auvelity, REXULTI, VRAYLAR, ARISTADA, Jornay PM, AUSTEDO XR.
Industry payments across WA — which companies pay providers there.
